KPV received a favorable PCAC recommendation for the Section 503A Bulks List, delivering the second major peptide win of July 23.
KPV joined BPC-157 on the winning side of the July 2026 Pharmacy Compounding Advisory Committee meeting.
The favorable recommendation added momentum for KPV's inclusion on the Section 503A Bulks List and strengthened a remarkable Day 1 for peptide compounding.
KPV's favorable PCAC result
PCAC delivered a favorable recommendation on KPV during the July 23 meeting. It followed two favorable 8–6–1 results for BPC-157 and came before another favorable 8–6–1 result for TB-500.
That made KPV the middle win in a three-peptide run that put the 503A Bulks List at the center of the national peptide story.
Why KPV was before PCAC
FDA scheduled questions on KPV free base and KPV acetate for possible inclusion on the Section 503A Bulks List.
The KPV nomination presented to the committee focused on wound healing and inflammatory conditions. Written materials described the peptide's physical and chemical characterization, safety record, evidence of effectiveness, and historical use in compounding.
The real-world KPV record
The KPV nomination materials documented 361,643 units of medication containing KPV across data compiled from six manufacturers and five clinics. Of those, 34,318 were standalone KPV products, with reporting periods spanning 2018 to 2026.
That record gave the committee a substantial view of KPV's existing use in compounded and clinic-dispensed products.
KPV joins BPC-157 and TB-500
Day 1 produced favorable results for three peptides:
- BPC-157: favorable free-base and acetate recommendations
- KPV: favorable committee recommendation
- TB-500: favorable 8–6–1 result
Read the complete PCAC Day 1 results or see how the votes connect to the 503A Bulks List.
Follow every PCAC peptide vote
Rebody's PCAC live stream and peptide vote tracker covers KPV, BPC-157, TB-500, MOTS-c, emideltide, Epitalon, and Semax.
KPV PCAC FAQ
How did PCAC vote on KPV?
KPV received a favorable committee recommendation during the July 23, 2026 PCAC meeting.
Why was KPV reviewed by PCAC?
PCAC reviewed KPV free base and acetate for possible inclusion on the Section 503A Bulks List.
Which other peptides received favorable Day 1 results?
BPC-157 and TB-500 also received favorable PCAC results.